SynthesisObesity surgery2026
Sleeve Gastrectomy Versus Roux-en-Y Gastric Bypass in Terms of Hypertension Remission Rate After Surgery: A Meta-Analysis.
Synthesis in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTo compare the effects of sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB) on obesity-associated hypertension and weight loss in Chinese patients.
methodsWe systematically searched the Cochrane, PubMed, Web of Science, Scopus and Embase databases for studies comparing SG and RYGB, focusing on obesity treatment and blood pressure improvement, up to October 2025. Two independent authors extracted data, assessed quality, and statistically analyzed the included studies, The risk if bias was assessed using Cochrane 's tool for randomized trials and the Newcastle-Ottawa Scale for cohort studies.
resultsFourteen studies (two randomized controlled trials and twelve cohort studies) encompassing 3234 patients (1725 SG, 1509 RYGB) were included. There was no significant difference in overall excess weight loss (%EWL) and total weight loss(%TWL) between SG and RYGB (MD=-1.55, 95%CI [-6.64,3.53], P > 0.05) and (MD = 2.09, 95%CI [-0.92,5.09], P > 0.05).RYGB showed superior long-term (> 1 year) %EWL compared to SG (MD=-8.32, 95%CI [-12.14, -4.49], P < 0.05). Hypertension remission rates were similar between SG and RYGB (OR = 0.93, 95% CI [0.60, 1.44], P > 0.05), regardless of age or follow-up duration. There were no significant differences in systolic or diastolic blood pressure improvements between the two procedures.
conclusionBoth procedures effectively improve hypertension remission in patients with obesity in China, with no significant difference between them. Regarding weight loss, while short-term outcomes are similar, RYGB achieves superior long-term %EWL, indicating its greater potential for sustained weight maintenance.
Indexed as
Identifiers
41436715What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.